Author of

• 32243

  +

  EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Treatment in the Real World - Support, Survivorship, Systems Research
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32271

    +

    EP1.16-27 - Observational Study to Investigate the Implementation Rate of Re-Biopsy in EGFR-TKI-Resistant Patients (NLCTG1602) (Now Available) (ID 1051)

    08:00 - 18:00  |  Author(s): Yoshiki Hayashi
    • Abstract
    • Slides

    Background
    

    In EGFR-TKI treatment, cannot perform re-biopsy in all cases for recurrent style and involvement.
    In the case that only cytodiagnosis can gather, we cannot perform an examination for T790M by the Cobas method even if we can obtain a specimen.The examination of plasma is useful, but the case which cannot but provide the next treatment as we cannot confirm a resistant mechanism may often occur by the true clinic because we cannot detect all resistance.
    

    Method
    

    Examine the rate of use of re-biopsy in the EGFR-TKI-resistant case of the EGFR mutation in the gene-positive progress non-small cell lung cancer and histological diagnosis and rate of agreement of the T790M mutation detection by the Cobas method of the cytodiagnosis prospectively.
    ＜subjects>Treated by EGFR-TKI, and do the case that an effect was able to continue with primary registration, and do it with the second registration when treatment was resistant, and do the laboratory procedure and results with registration when there are a recurrence point, PS, use or nonuse of re-biosy.
    We added up the liquid as re-biosy after July, 2017.
    

    Result
    

    Start registration of this study in February, 2017, and 197 primary registration, second registration completion become 127 cases as of January, 2019.We conducted the interim analysis in 80 second registration in October, 2018.
    The Re-biopsy rate of use was 74/80 = 92.5%.The re-biopsy success rate was the whole, and 79.7%, the T790M positive rate were 41.9%.By the specimen distinction, the histological diagnosis, the cytodiagnosis, the re-biopsy success rate and the T790M positive rate by the examination of plasma were 92.3% /56.4%, 83.3%/8.3%, 56.5%/34 .8%, respectively.
    It is during data cleaning work and is going to report end results now at the general meeting.
    

    Conclusion
    

    Section not applicable

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.